Comparative Pharmacology
Head-to-head clinical analysis: MAGNACORT versus OTIPRIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNACORT versus OTIPRIO.
MAGNACORT vs OTIPRIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid receptor agonist; modulates gene transcription to produce anti-inflammatory and immunosuppressive effects.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, leading to inhibition of DNA replication and transcription.
5 mg orally once daily for 7 days, then 5 mg orally every other day for 7 days. Alternatively, 1 mg/kg intravenously every 12 hours for 14 days.
1 mg/kg intravenous infusion over 1 hour every 12 hours; typical adult dose is 100 mg every 12 hours.
None Documented
None Documented
3.5 ± 0.8 hours (terminal); prolonged in renal impairment (up to 12 hours in ESRD) and hepatic disease; requires dose adjustment in CrCl <30 mL/min
Mean terminal elimination half-life is approximately 4.5 hours (range 3-6 hours); prolonged in renal impairment requiring dose adjustment.
Renal (80% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion); biliary/fecal (15%)
Primarily renal excretion of unchanged drug (approximately 80% over 24 hours) via glomerular filtration; biliary/fecal elimination accounts for <5%.
Category C
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid